Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MMSI 
Merit Medical Systems Inc (MMSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: MMSI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $104.73
1 Year Target Price $104.73
| 4 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.75% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.16B USD | Price to earnings Ratio 44.67 | 1Y Target Price 104.73 |
Price to earnings Ratio 44.67 | 1Y Target Price 104.73 | ||
Volume (30-day avg) 10 | Beta 0.61 | 52 Weeks Range 78.12 - 111.45 | Updated Date 11/6/2025 |
52 Weeks Range 78.12 - 111.45 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-23 | When - | Estimate 0.826 | Actual 0.92 |
Profitability
Profit Margin 8.02% | Operating Margin (TTM) 11.1% |
Management Effectiveness
Return on Assets (TTM) 4.28% | Return on Equity (TTM) 8.3% |
Valuation
Trailing PE 44.67 | Forward PE 20.96 | Enterprise Value 5361942387 | Price to Sales(TTM) 3.5 |
Enterprise Value 5361942387 | Price to Sales(TTM) 3.5 | ||
Enterprise Value to Revenue 3.74 | Enterprise Value to EBITDA 17.46 | Shares Outstanding 59290248 | Shares Floating 57864318 |
Shares Outstanding 59290248 | Shares Floating 57864318 | ||
Percent Insiders 2.32 | Percent Institutions 108.46 |
Upturn AI SWOT
Merit Medical Systems Inc
Company Overview
History and Background
Merit Medical Systems, Inc. was founded in 1987 by Fred P. Lampropoulos. It has grown through internal development and acquisitions, focusing on developing and manufacturing devices used in interventional, diagnostic, and therapeutic procedures.
Core Business Areas
- Cardiovascular: Products for interventional cardiology and electrophysiology, including inflation devices, diagnostic and therapeutic catheters, and hemostasis products.
- Peripheral Intervention: Products used in peripheral vascular procedures, such as embolization devices, drainage catheters, and guidewires.
- Interventional Oncology & Spine: Products for targeted cancer therapies and spine procedures, including microcatheters, drug-eluting beads, and vertebral augmentation systems.
- Endoscopy: Products for Gastrointestinal procedures
- Original Equipment Manufacturing (OEM): Merit provides OEM services for other medical device companies
Leadership and Structure
Fred P. Lampropoulos is the Chairman and CEO. The company operates with a functional organizational structure, with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- EmboSphere Microspheres: Embolization product used in interventional oncology for the treatment of liver cancer. Competitors include Boston Scientific and Cook Medical. Market share data is difficult to obtain, but Merit is considered a significant player in this segment.
- Concerto ONYX Detachable Tip Micro Catheter: A microcatheter used in neurovascular procedures. Competitors include Medtronic and Stryker. Market share data is not readily available, but the Concerto is a key product for Merit.
- Inflation Devices: Used for stent and balloon catheter delivery, Merit holds significant market share in the inflation device market within cardiology and peripheral interventions. Competitors include Boston Scientific and Medtronic.
- Heiss Steerable Guidewire: A guidewire used for peripheral interventions. Competitors include Boston Scientific and Medtronic.
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, stringent regulatory requirements, and increasing demand due to aging populations and minimally invasive procedures.
Positioning
Merit Medical is positioned as a provider of niche products in interventional medicine. Its competitive advantage lies in its focused product portfolio, strong relationships with physicians, and ability to quickly bring new products to market.
Total Addressable Market (TAM)
The TAM for interventional medical devices is estimated to be in the tens of billions of dollars annually. Merit is positioned to capture a portion of this TAM through its specialized product offerings, with a significant runway for growth in areas like interventional oncology and peripheral interventions. The market is expected to grow due to increased prevalence of diseases and growing awareness of advanced diagnostic and therapeutic procedures
Upturn SWOT Analysis
Strengths
- Focused product portfolio in interventional medicine
- Strong relationships with physicians
- Ability to quickly bring new products to market
- Strong brand recognition
- Strategic acquisition experience
Weaknesses
- Smaller size compared to major competitors
- Dependence on key products
- Geographic concentration of manufacturing in Utah
- Pricing pressure from larger competitors
- Reliance on third party suppliers
Opportunities
- Expanding product offerings in high-growth areas like interventional oncology
- Geographic expansion into emerging markets
- Acquisitions of complementary technologies
- Increasing adoption of minimally invasive procedures
- Partnerships with larger medical device companies
Threats
- Increasing competition from larger medical device companies
- Price pressure from healthcare providers
- Changes in healthcare regulations
- Product liability risks
- Economic downturns
Competitors and Market Share
Key Competitors
- BSX
- MDT
- JNJ
Competitive Landscape
Merit Medical competes with larger medical device companies. Its competitive advantage is its focused product portfolio and agility. It competes directly on pricing and features and by offering niche procedures that complement the larger players' devices.
Major Acquisitions
BDC
- Year: 2023
- Acquisition Price (USD millions): 65
- Strategic Rationale: Expanded Merit's access device portfolio.
MedStream Devices
- Year: 2023
- Acquisition Price (USD millions): 23
- Strategic Rationale: Expanded Merit's thrombolytic portfolio.
Temptation Medical Systems, Inc.
- Year: 2023
- Acquisition Price (USD millions): 80
- Strategic Rationale: Expanded Merit's cardiac rhythm management device portfolio.
Growth Trajectory and Initiatives
Historical Growth: Merit Medical has experienced moderate growth through internal development and strategic acquisitions.
Future Projections: Analyst estimates suggest continued growth, driven by new product launches and market expansion. Growth is expected to be between 5% and 10%.
Recent Initiatives: Recent initiatives include new product development in interventional oncology, expansion into emerging markets, and strategic acquisitions to broaden the product portfolio.
Summary
Merit Medical is a specialized player in the interventional medical device market. Its focus on niche products and strong relationships with physicians are working well. Key areas to watch include increasing competition and potential price pressures. However, the companyu2019s recent acquisitions and expanding product offerings provide a solid growth trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q), Investor presentations, Analyst reports, Company Website, Yahoo Finance
Disclaimers:
The data provided is based on publicly available information and analyst estimates. Actual results may vary. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Merit Medical Systems Inc
Exchange NASDAQ | Headquaters South Jordan, UT, United States | ||
IPO Launch date 1990-08-09 | President, CEO & Director Ms. Martha Goldberg Aronson | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 7400 | Website https://www.merit.com |
Full time employees 7400 | Website https://www.merit.com | ||
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures, as well as non-pharmacological treatment of gastroesophageal reflux disease. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.